PARP inhibitors

AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
Sat, 09/28/19 - 05:00 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
Thu, 09/26/19 - 12:33 pm
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
ESMO 2019 preview – PARPs on parade
EP Vantage
Thu, 09/5/19 - 12:06 pm
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ
Pharmaforum
Thu, 09/5/19 - 10:15 am
AstraZeneca
Theragnostics
PARP inhibitors
diagnostics
cancer
Clovis investors lose faith as Rubraca struggles against Big Pharma's marketing giants
Fierce Pharma
Fri, 08/2/19 - 12:43 pm
Clovis Oncology
Rubraca
PARP inhibitors
Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how
Endpoints
Thu, 05/16/19 - 11:51 am
AstraZeneca
cediranib
ovarian cancer
Yale
PARP inhibitors
Early pancreatic cancer data give Clovis a new path in PARP market
Biopharma Dive
Tue, 04/2/19 - 04:22 pm
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
Xconomy
Mon, 12/3/18 - 10:11 am
GSK
M&A
Tesaro
PARP inhibitors
Zejula
AstraZeneca
PARP makers search for a way to break through
Biopharma Dive
Fri, 11/9/18 - 12:08 am
AstraZeneca
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
Mammoth Lynparza survival win puts AZ, Merck in line for $1B launch
Fierce Pharma
Sun, 10/21/18 - 11:33 pm
AstraZeneca
Merck
Lynparza
PARP inhibitors
BRCA-mutated ovarian cancer
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?
Fierce Pharma
Thu, 10/18/18 - 12:15 am
Pfizer
breast cancer
PARP inhibitors
Talzenna
FDA approves Pfizer's drug for advanced breast cancer
Reuters
Tue, 10/16/18 - 08:40 pm
FDA
Pfizer
PARP inhibitors
talazoparib
breast cancer
BRCA-mutant breast cancer
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
Thu, 08/9/18 - 10:04 pm
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Lilly Asian Ventures backs Impact’s PARP research again, chipping in for $30M Series C led by Decheng Capital
Endpoints
Sat, 08/4/18 - 12:14 pm
Chian
PARP inhibitors
Lilly Asian Ventures
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
Sat, 03/10/18 - 09:17 am
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo
Fierce Pharma
Tue, 02/27/18 - 06:45 pm
Roche
Tecentriq
bladder cancer
Zejula
PARP inhibitors
In a pioneering first, AstraZeneca scores FDA OK to use its PARP against breast cancer
Endpoints
Fri, 01/12/18 - 10:39 am
AstraZeneca
PARP inhibitors
FDA
Lynparza
metastatic breast cancer
A New PARP Drug For Breast Cancer
Forbes
Mon, 12/18/17 - 10:13 am
PARP inhibitors
breast cancer
metastatic breast cancer
talazoparib
Pfizer
In a showdown with AstraZeneca, Pfizer posts solid — and very familiar — PhIII breast cancer data for talazoparib
Endpoints
Fri, 12/8/17 - 11:46 am
Pfizer
AstraZeneca
talazoparib
advanced breast cancer
Lynparza
PARP inhibitors

Pages